Revive Therapeutics Logo White

Revive Therapeutics

CSE: RVV | OTC: RVVTF 

Revive Therapeutics is focused on the R&D and sale of cannabinoid-based products, recently expanding into the psychedelics industry more broadly.

[mstock id="3029"]
[mstock id="3030"]

Latest News

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19

May 2, 2023

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

April 3, 2023

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

March 28, 2023

Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

March 20, 2023

Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

March 8, 2023

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

February 6, 2023

Join our Newsletter

Get the latest Company updates delivered to straight to your inbox.